ArticleFrontiers in oncology2023

Receptor-ligand pair typing and prognostic risk model of response or resistance to immune checkpoint inhibitors in lung adenocarcinoma.

Shengqiang Mao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.